查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026783

骨髓增生性疾病市場預測至2034年：按類型、診斷和篩檢方法、治療方法、最終用戶和地區分類的全球分析

Myeloproliferative Disorders Market Forecasts to 2034 - Global Analysis By Type, Diagnosis and Screening Methods, Treatment Option, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球骨髓增生性疾病市場規模將達到 99.761 億美元，在預測期內以 10.3% 的複合年成長率成長，到 2034 年將達到 218.559 億美元。

一組罕見的血液疾病，稱為骨髓增生性疾病（MPD），其特徵是骨髓中成熟血球過度增生。紅血球、白血球和血小板等細胞都會受到這種異常增生的影響。定期監測對於控制病情和預防其發展為急性白血病至關重要。治療目標是最大限度地減輕症狀、減少併發症並阻止疾病進展。

根據國際癌症研究機構 (IARC) 提供的 2021 年數據，2020 年歐洲地區的癌症患者人數為 479 萬，但預計到 2040 年將增加到 607 萬人。

對該疾病的認知提高

隨著公眾和醫療專業人員對骨髓增生性疾病（MPD）的認知不斷提高，這些疾病的早期檢測也取得了進展。宣傳宣傳活動、醫療保健舉措和倡導活動對於提高公眾認知至關重要，這也促使人們對創新治療方法和治療方法的需求不斷成長。因此，總體而言，公眾對MPD認知的提高透過促進早期療育和提高患者標準護理質量，對MPD產生了積極影響，從而推動了市場規模的擴大。

高昂的醫療費用

政府和保險公司可能難以應付為骨髓增生性疾病（MPD）患者提供各種昂貴治療所帶來的經濟負擔。藥物、療法以及可能的幹細胞移植等高昂費用會對患者和醫療保健系統造成沉重的經濟負擔，並可能影響整體治療效果。因此，高昂的治療費用是MPD市場面臨的主要阻礙因素。

診斷技術的進步

分子譜分析、影像學和基因檢測領域的新進展正在提高骨髓增生性疾病（MPD）診斷的準確性和有效性。改進的診斷技術有助於快速干涉，延緩疾病進展及其影響。此外，診斷技術的持續研發表明，人們致力於最佳化骨髓增生性疾病的診斷，並支持醫療專業人員做出明智的決策，從而逐步推動市場擴張。

藥物發現中的遺傳複雜性

在藥物研發中，識別適用於骨髓增生性疾病（MPD）所有遺傳頻譜的通用分子標靶是一項挑戰。這種複雜性使得通用標靶治療的開發舉步維艱。每種亞型可能需要獨特的治療方法，包括JAK2、CALR和MPL基因的突變，從而導致不同的疾病表現型。此外，根治性治療方法的開發和對複雜分子機制的持續研究也受到阻礙，進而限制了市場區隔領域的擴張。

新冠疫情的感染疾病

疫情擾亂了常規醫療服務，導致許多骨髓增生性疾病（MPD）患者的診斷和治療啟動被延誤，其中包括真性紅血球增多症、原發性血小板增多症和骨髓纖維化患者。此外，免疫系統減弱和感染疾病易感性增加也使這些患者面臨更高的風險。因此，由於這些因素共同影響患者照護和整體市場擴張，骨髓增生性疾病市場面臨許多挑戰。

預計在預測期內，真性多血症（PV）患者群體將最大。

真性多血症症 (PV) 預計將佔據最大的市場佔有率。 PV 的特徵是骨髓疾病，可導致血液黏度增加、凝血功能障礙和心血管問題。目前的研究目標是開發新的治療方法改善真性紅血球增多症 (PV) 患者的生活品質、控制症狀並降低血栓症的風險。因此，骨髓增生性疾病市場的特徵在於疾病控制與改善患者整體健康狀況之間的微妙平衡，而這正是推動該細分市場擴張的原因。

預計在預測期內，骨髓切片檢查領域將呈現最高的複合年成長率。

預計在預測期內，骨髓切片檢查領域將呈現最高的複合年成長率。這是因為骨髓切片檢查是識別細胞生成異常和評估骨髓健康的重要診斷方法。骨髓切片檢查對於了解基因突變、細胞形態以及骨髓增生性疾病的病程至關重要。此外，研究人員正在進行實驗，以改善切片檢查技術並有效利用分子層面的見解，這將提高診斷效用，並有助於制定更好的疾病治療方案，從而推動該領域的成長。

市佔率最大的地區：

在預測期內，亞太地區佔據最大的市場佔有率，這主要得益於各國政府和醫療機構所進行的合作宣傳活動、診斷技術的進步以及尖端治療手段的普及。該地區的主要企業和國家，包括中國、日本和印度，在骨髓增生性疾病（MPD）創新治療方法的研發方面投入了巨大力量。因此，包括標靶治療和幹細胞移植在內的先進治療方法得以引入，進一步推動了該地區的成長。

複合年成長率最高的地區：

預計北美地區在預測期內將實現最高的複合年成長率，這得益於先進的診斷工具，例如分子檢測和基因譜分析，這些工具能夠精準識別疾病。巨量資料分析和人工智慧的進步正在推動對骨髓增生性疾病（MPD）更全面的了解，並促進個人化治療策略的發展。此外，標靶治療（例如Janus激酶 (JAK) 抑制劑）的普及，在提高療效的同時最大限度地減少副作用，也推動了該地區的擴張。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球骨髓增生性疾病市場：依類型分類

  • 真性紅血球增多症
  • 慢性骨髓性白血病（CML）
  • 原發性纖維化
  • 原發性血小板增多症
  • 其他類型

第6章 全球骨髓增生性疾病市場：依診斷及篩檢法分類

  • 骨髓切片檢查
  • 驗血
  • 基因檢測

第7章 全球骨髓增生性疾病市場：依治療方法

  • 骨髓移植
  • 治療方法
  • 支持性護理
  • 藥物
  • 化療
  • 其他治療方法

第8章 全球骨髓增生性疾病市場：依最終用戶分類

  • 製藥公司
  • 研究機構
  • 醫院和診所
  • 其他最終用戶

第9章 全球骨髓增生性疾病市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Novartis AG
  • Teva Pharmaceutical Industries
  • AbbVie
  • Bristol Myers Squibb（BMS）
  • Roche
  • Incyte Corporation
  • Gilead Sciences
  • MP Biomedicals
  • Mylan
  • Roxall Medizin
  • AOP Orphan Pharmaceuticals AG
  • CTI BioPharma Corp
  • Promedior, Inc.
  • Celgene
Product Code: SMRC24584

According to Stratistics MRC, the Global Myeloproliferative Disorders Market is accounted for $9976.1 million in 2026 and is expected to reach $21855.9 million by 2034 growing at a CAGR of 10.3% during the forecast period. A class of uncommon blood diseases known as myeloproliferative disorders (MPDs) is defined by the bone marrow's overproduction of mature blood cells. Red blood cells, white blood cells, and platelets are among the cells that are impacted by this aberrant proliferation. Regular monitoring is crucial for disease management and to prevent potential progression to acute leukemia. The goals of management are to minimize symptoms, cut down on complications, and stop the condition from getting worse.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Rising demand in disease awareness

Myeloproliferative Disorders (MPDs) among the general public and healthcare professionals are detected by improving recognition of these conditions. Campaigns for education, healthcare initiatives, and advocacy are essential in spreading awareness and there is a corresponding increase in demand for innovative treatments and therapies. Thus, all things considered, increased awareness of the disease has a positive impact on the MPD by encouraging early intervention and enhancing the standard of care for those who are affected which is driving the market size.

Restraint:

High cost treatment

Governments and insurance companies might find it difficult to handle the financial strain of offering extensive and expensive treatments for myeloproliferative disorder (MPD). Patients and healthcare systems bear a financial burden due to the high costs of medications, therapies, and possible stem cell transplants potentially impacting their overall health outcomes. Therefore, the high cost of treatment serves as a significant restraint in the myeloproliferative disorder (MPD) market.

Opportunity:

Technological advancements in diagnosis

New developments in molecular profiling, imaging, and genetic testing improve the precision and efficacy of MPD diagnosis. Improved diagnostic skills also make it easier to intervene quickly, which slows the course of the illness and its consequences. In addition, continuous research and development in diagnostic technologies demonstrates a dedication in optimizing the diagnosis of myeloproliferative disorders, assisting medical professionals in making well-informed decisions, and therefore gradually driving market expansion.

Threat:

Genetic complexities in drug development

Drug development efforts face obstacles in identifying common molecular targets applicable across the genetic spectrum of MPDs. This complexity makes it challenging to develop universal targeted therapies, as each subtype may require a distinct approach including mutations in JAK2, CALR, and MPL genes, leading to varied disease phenotypes. In addition, the development of curative therapies and ongoing research to intricate molecular mechanisms are decreased thereby hampering the segment expansion.

Covid-19 Impact

The pandemic has disrupted routine healthcare services, leading to delayed diagnoses and treatment initiation for many MPD patients, including conditions like polycythemia vera, essential thrombocythemia, and myelofibrosis, face heightened risks due to compromised immune systems and increased susceptibility to infections. Therefore, the market for myeloproliferative disorders faced difficulties as a result of these combined factors, which have an impact on patient care and market expansion overall.

The polycythemia vera (PV) segment is expected to be the largest during the forecast period

The Polycythemia Vera (PV) segment is estimated to hold the largest share. PV is characterized by a disorder of the bone marrow that can cause high blood viscosity, clotting, and cardiovascular problems. The goal of ongoing research is to create novel therapies that will help PV patients live better, manage their symptoms, and lower their risk of thrombosis. Thus, the myeloproliferative disorders market is characterized by a delicate balance between disease control and improving patients' overall well-being which is driving this segment expansion.

The bone marrow biopsy segment is expected to have the highest CAGR during the forecast period

The bone marrow biopsy segment is anticipated to have highest CAGR during the forecast period. It is a diagnostic process that is essential for determining abnormalities in cell production and evaluating the health of the bone marrow. They are crucial for learning about genetic mutations, cell morphology, and the course of myeloproliferative disorders. In addition, researchers are conducting experiments to improve biopsy methods and make better use of molecular insights, which will increase their diagnostic utility and help in developing better treatment plans for these conditions which are boosting this segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to governments and healthcare organizations which work together in raising awareness, advance diagnostic skills, and guarantee access to cutting-edge treatments. Key players and key countries in the region, including China, Japan, and India, have witnessed a surge in research and development activities focused on innovative therapies for MPDs. Therefore, this has resulted in introducing advanced treatment options, including targeted therapies and stem cell transplantation which further propel the growth of the region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to sophisticated diagnostic tools that allow for accurate disease identification, like molecular testing and genetic profiling. These developments in big data analytics and artificial intelligence support more comprehensive knowledge of MPDs and customized treatment strategies. Moreover, people are turning to targeted therapies, such as Janus kinase (JAK) inhibitors, which increase treatment efficacy while minimizing side effects, which are driving the region's expansion.

Key players in the market

Some of the key players in the Myeloproliferative Disorders Market include Novartis AG, Teva Pharmaceutical Industries, AbbVie, Bristol Myers Squibb (BMS), Roche, Incyte Corporation, Gilead Sciences, MP Biomedicals, Mylan, Roxall Medizin, AOP Orphan Pharmaceuticals AG, CTI BioPharma Corp, Promedior, Inc. and Celgene.

Key Developments:

In October 2023, Allergan Aesthetics, an AbbVie company announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.

In September 2023, Ionis Pharmaceuticals, Inc. announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).

In August 2023, Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq(R) SC (atezolizumab), using Halozyme's ENHANZE(R) drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.

In July 2023, DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON(TM)) platform, announced that it has been acquired by Novartis.

Types Covered:

  • Polycythemia Vera
  • Chronic Myeloid Leukemia (CML)
  • Primary Myelofibrosis
  • Essential Thrombocythemia
  • Other Types

Diagnosis and Screening Methods Covered:

  • Bone Marrow Biopsy
  • Blood Tests
  • Genetic Testing

Treatment Options Covered:

  • Bone Marrow Transplant
  • Therapeutic Procedures
  • Supportive Care
  • Medications
  • Chemotherapy
  • Other Treatment Options

End Users Covered:

  • Pharmaceutical Companies
  • Research Institutions
  • Hospitals and Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myeloproliferative Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Polycythemia Vera
  • 5.3 Chronic Myeloid Leukemia (CML)
  • 5.4 Primary Myelofibrosis
  • 5.5 Essential Thrombocythemia
  • 5.6 Other Types

6 Global Myeloproliferative Disorders Market, By Diagnosis and Screening Methods

  • 6.1 Introduction
  • 6.2 Bone Marrow Biopsy
  • 6.3 Blood Tests
  • 6.4 Genetic Testing

7 Global Myeloproliferative Disorders Market, By Treatment Option

  • 7.1 Introduction
  • 7.2 Bone Marrow Transplant
  • 7.3 Therapeutic Procedures
  • 7.4 Supportive Care
  • 7.5 Medications
  • 7.6 Chemotherapy
  • 7.7 Other Treatment Options

8 Global Myeloproliferative Disorders Market, By End Users

  • 8.1 Introduction
  • 8.2 Pharmaceutical Companies
  • 8.3 Research Institutions
  • 8.4 Hospitals and Clinics
  • 8.5 Other End Users

9 Global Myeloproliferative Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Teva Pharmaceutical Industries
  • 11.3 AbbVie
  • 11.4 Bristol Myers Squibb (BMS)
  • 11.5 Roche
  • 11.6 Incyte Corporation
  • 11.7 Gilead Sciences
  • 11.8 MP Biomedicals
  • 11.9 Mylan
  • 11.10 Roxall Medizin
  • 11.11 AOP Orphan Pharmaceuticals AG
  • 11.12 CTI BioPharma Corp
  • 11.13 Promedior, Inc.
  • 11.14 Celgene

List of Tables

  • Table 1 Global Myeloproliferative Disorders Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Myeloproliferative Disorders Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2023-2034) ($MN)
  • Table 4 Global Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2023-2034) ($MN)
  • Table 5 Global Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2023-2034) ($MN)
  • Table 6 Global Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2023-2034) ($MN)
  • Table 7 Global Myeloproliferative Disorders Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 8 Global Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2023-2034) ($MN)
  • Table 9 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2023-2034) ($MN)
  • Table 10 Global Myeloproliferative Disorders Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 11 Global Myeloproliferative Disorders Market Outlook, By Genetic Testing (2023-2034) ($MN)
  • Table 12 Global Myeloproliferative Disorders Market Outlook, By Treatment Option (2023-2034) ($MN)
  • Table 13 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2023-2034) ($MN)
  • Table 14 Global Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2023-2034) ($MN)
  • Table 15 Global Myeloproliferative Disorders Market Outlook, By Supportive Care (2023-2034) ($MN)
  • Table 16 Global Myeloproliferative Disorders Market Outlook, By Medications (2023-2034) ($MN)
  • Table 17 Global Myeloproliferative Disorders Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 18 Global Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2023-2034) ($MN)
  • Table 19 Global Myeloproliferative Disorders Market Outlook, By End Users (2023-2034) ($MN)
  • Table 20 Global Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 21 Global Myeloproliferative Disorders Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 22 Global Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 23 Global Myeloproliferative Disorders Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 24 North America Myeloproliferative Disorders Market Outlook, By Country (2023-2034) ($MN)
  • Table 25 North America Myeloproliferative Disorders Market Outlook, By Type (2023-2034) ($MN)
  • Table 26 North America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2023-2034) ($MN)
  • Table 27 North America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2023-2034) ($MN)
  • Table 28 North America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2023-2034) ($MN)
  • Table 29 North America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2023-2034) ($MN)
  • Table 30 North America Myeloproliferative Disorders Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 31 North America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2023-2034) ($MN)
  • Table 32 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2023-2034) ($MN)
  • Table 33 North America Myeloproliferative Disorders Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 34 North America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2023-2034) ($MN)
  • Table 35 North America Myeloproliferative Disorders Market Outlook, By Treatment Option (2023-2034) ($MN)
  • Table 36 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2023-2034) ($MN)
  • Table 37 North America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2023-2034) ($MN)
  • Table 38 North America Myeloproliferative Disorders Market Outlook, By Supportive Care (2023-2034) ($MN)
  • Table 39 North America Myeloproliferative Disorders Market Outlook, By Medications (2023-2034) ($MN)
  • Table 40 North America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 41 North America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2023-2034) ($MN)
  • Table 42 North America Myeloproliferative Disorders Market Outlook, By End Users (2023-2034) ($MN)
  • Table 43 North America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 44 North America Myeloproliferative Disorders Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 45 North America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 46 North America Myeloproliferative Disorders Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 47 Europe Myeloproliferative Disorders Market Outlook, By Country (2023-2034) ($MN)
  • Table 48 Europe Myeloproliferative Disorders Market Outlook, By Type (2023-2034) ($MN)
  • Table 49 Europe Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2023-2034) ($MN)
  • Table 50 Europe Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2023-2034) ($MN)
  • Table 51 Europe Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2023-2034) ($MN)
  • Table 52 Europe Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2023-2034) ($MN)
  • Table 53 Europe Myeloproliferative Disorders Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 54 Europe Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2023-2034) ($MN)
  • Table 55 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2023-2034) ($MN)
  • Table 56 Europe Myeloproliferative Disorders Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 57 Europe Myeloproliferative Disorders Market Outlook, By Genetic Testing (2023-2034) ($MN)
  • Table 58 Europe Myeloproliferative Disorders Market Outlook, By Treatment Option (2023-2034) ($MN)
  • Table 59 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2023-2034) ($MN)
  • Table 60 Europe Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2023-2034) ($MN)
  • Table 61 Europe Myeloproliferative Disorders Market Outlook, By Supportive Care (2023-2034) ($MN)
  • Table 62 Europe Myeloproliferative Disorders Market Outlook, By Medications (2023-2034) ($MN)
  • Table 63 Europe Myeloproliferative Disorders Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 64 Europe Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2023-2034) ($MN)
  • Table 65 Europe Myeloproliferative Disorders Market Outlook, By End Users (2023-2034) ($MN)
  • Table 66 Europe Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 67 Europe Myeloproliferative Disorders Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 68 Europe Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 69 Europe Myeloproliferative Disorders Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 70 Asia Pacific Myeloproliferative Disorders Market Outlook, By Country (2023-2034) ($MN)
  • Table 71 Asia Pacific Myeloproliferative Disorders Market Outlook, By Type (2023-2034) ($MN)
  • Table 72 Asia Pacific Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2023-2034) ($MN)
  • Table 73 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2023-2034) ($MN)
  • Table 74 Asia Pacific Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2023-2034) ($MN)
  • Table 75 Asia Pacific Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2023-2034) ($MN)
  • Table 76 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 77 Asia Pacific Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2023-2034) ($MN)
  • Table 78 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2023-2034) ($MN)
  • Table 79 Asia Pacific Myeloproliferative Disorders Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 80 Asia Pacific Myeloproliferative Disorders Market Outlook, By Genetic Testing (2023-2034) ($MN)
  • Table 81 Asia Pacific Myeloproliferative Disorders Market Outlook, By Treatment Option (2023-2034) ($MN)
  • Table 82 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2023-2034) ($MN)
  • Table 83 Asia Pacific Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2023-2034) ($MN)
  • Table 84 Asia Pacific Myeloproliferative Disorders Market Outlook, By Supportive Care (2023-2034) ($MN)
  • Table 85 Asia Pacific Myeloproliferative Disorders Market Outlook, By Medications (2023-2034) ($MN)
  • Table 86 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 87 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2023-2034) ($MN)
  • Table 88 Asia Pacific Myeloproliferative Disorders Market Outlook, By End Users (2023-2034) ($MN)
  • Table 89 Asia Pacific Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 90 Asia Pacific Myeloproliferative Disorders Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 91 Asia Pacific Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 92 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 93 South America Myeloproliferative Disorders Market Outlook, By Country (2023-2034) ($MN)
  • Table 94 South America Myeloproliferative Disorders Market Outlook, By Type (2023-2034) ($MN)
  • Table 95 South America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2023-2034) ($MN)
  • Table 96 South America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2023-2034) ($MN)
  • Table 97 South America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2023-2034) ($MN)
  • Table 98 South America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2023-2034) ($MN)
  • Table 99 South America Myeloproliferative Disorders Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 100 South America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2023-2034) ($MN)
  • Table 101 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2023-2034) ($MN)
  • Table 102 South America Myeloproliferative Disorders Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 103 South America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2023-2034) ($MN)
  • Table 104 South America Myeloproliferative Disorders Market Outlook, By Treatment Option (2023-2034) ($MN)
  • Table 105 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2023-2034) ($MN)
  • Table 106 South America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2023-2034) ($MN)
  • Table 107 South America Myeloproliferative Disorders Market Outlook, By Supportive Care (2023-2034) ($MN)
  • Table 108 South America Myeloproliferative Disorders Market Outlook, By Medications (2023-2034) ($MN)
  • Table 109 South America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 110 South America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2023-2034) ($MN)
  • Table 111 South America Myeloproliferative Disorders Market Outlook, By End Users (2023-2034) ($MN)
  • Table 112 South America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 113 South America Myeloproliferative Disorders Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 114 South America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 115 South America Myeloproliferative Disorders Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 116 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Country (2023-2034) ($MN)
  • Table 117 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Type (2023-2034) ($MN)
  • Table 118 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2023-2034) ($MN)
  • Table 119 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2023-2034) ($MN)
  • Table 120 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2023-2034) ($MN)
  • Table 121 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2023-2034) ($MN)
  • Table 122 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 123 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2023-2034) ($MN)
  • Table 124 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2023-2034) ($MN)
  • Table 125 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 126 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Genetic Testing (2023-2034) ($MN)
  • Table 127 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Treatment Option (2023-2034) ($MN)
  • Table 128 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2023-2034) ($MN)
  • Table 129 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2023-2034) ($MN)
  • Table 130 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Supportive Care (2023-2034) ($MN)
  • Table 131 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Medications (2023-2034) ($MN)
  • Table 132 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 133 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2023-2034) ($MN)
  • Table 134 Middle East & Africa Myeloproliferative Disorders Market Outlook, By End Users (2023-2034) ($MN)
  • Table 135 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 136 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 137 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 138 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other End Users (2023-2034) ($MN)